Tivic Health Systems Partners with Scorpius BioManufacturing

Tivic Health Systems ( (TIVC) ) has provided an update.

On May 9, 2025, Tivic Health Systems entered into an agreement with Scorpius BioManufacturing to serve as the primary U.S. manufacturer for its TLR5 agonist, Entolimod, intended for the treatment of acute radiation syndrome. The agreement, valued at approximately $4.1 million, includes various manufacturing and development services to prepare for an FDA Biological Licensing application. This partnership aims to streamline the manufacturing process and enhance Tivic’s market positioning by ensuring a leaner supply chain and domestic production, with potential implications for commercial success and stakeholder value.

Spark’s Take on TIVC Stock

According to Spark, TipRanks’ AI Analyst, TIVC is a Neutral.

The overall stock score of 43 reflects Tivic Health Systems’ current financial difficulties, including declining revenues and negative profitability. However, recent strategic initiatives and corporate events provide some optimism for future growth. The stock’s technical indicators and valuation remain weak, necessitating significant improvements in financial performance and market sentiment to enhance stock attractiveness.

To see Spark’s full report on TIVC stock, click here.

More about Tivic Health Systems

Tivic Health Systems, Inc. is a diversified therapeutics company that focuses on harnessing the power of the immune and autonomic nervous systems to combat disease and restore health. The company is known for developing non-invasive medical devices that target the vagus nerve, and its lead biopharma product candidate is the TLR5 agonist Entolimod for treating Acute Radiation Syndrome (ARS). Tivic Health’s first FDA-approved product, ClearUP, is designed to treat sinus pain and pressure.

Average Trading Volume: 1,329,389

Technical Sentiment Signal: Sell

Current Market Cap: $2.62M

For detailed information about TIVC stock, go to TipRanks’ Stock Analysis page.